No Data
No Data
Brokerage morning meeting highlights: Now is the right time for AI healthcare layout.
In today's Brokerage morning meeting, Sinolink proposed that the layout of AI in healthcare is timely; HTSC expressed a bullish outlook on the product upgrades and commercial breakthroughs of AI applications in China by 2025; China Securities Co.,Ltd. believes that the turning point in the IDC Industry is approaching, and a new cycle is expected to begin.
Hong Kong stocks fluctuated | CRO Concept stocks continued to surge in the morning, WUXI BIO (02269) and TIGERMED (03347) both rose over 9%.
In the early session, CRO Concept stocks continued to rise. As of the time of writing, WUXI BIO (02269) is up 9.59%, priced at 22.85 HKD; TIGERMED (03347) is up 9.09%, priced at 31.2 HKD; GENSCRIPT BIO (01548) is up 7.22%, priced at 11.88 HKD.
[Hong Kong Stock Connect] SHANDONG XINHUA (00719) has received registration approval from the National Medical Products Administration for empagliflozin tablets, which are suitable for the treatment of type 2 diabetes.
Jinwu Financial News | SHANDONG XINHUA (00719) announced that the company recently received the Drug Registration Certificate for Empagliflozin Tablets (10mg) approved and issued by the National Medical Products Administration. This product meets the relevant requirements for drug registration and is approved for registration. Empagliflozin Tablets are indicated for the treatment of type 2 diabetes; they are used in adult patients with symptomatic chronic heart failure to reduce the risk of hospitalization due to heart failure.
Express News | Shandong Xinhua Pharmaceutical: Canagliflozin tablets have obtained a Pharmaceutical registration certificate.
SHANDONG XINHUA (00719) has received the "Pharmaceutical Supplement Application Approval Notice" for Rosuvastatin Calcium Tablets (20mg; 10mg).
SHANDONG XINHUA (00719) announced that recently, the company received approval from the National Medical Products Administration for the issuance of Ruishu...
China Securities Co.,Ltd.: Policy encouragement + new technology promotion + overseas opportunities create new chances, maintaining a bullish outlook on the Innovative Drugs industry.
National policies encourage the development of Innovative Drugs, new technologies promote the rapid growth of the Industry, new opportunities arise for going overseas, and there is a continuous Bullish outlook for the Innovative Drugs Industry.